FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

General Information

Summary This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Clinical trials phase Phase 1
Start date (estimated) 2020-03-19
End date (estimated) 2039-05-31
Clinical feature
Label chronic lymphocytic leukemia
Link http://purl.obolibrary.org/obo/DOID_1040
Description A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.; Xref MGI.

Administrative Information

NCT number NCT04245722
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04245722
Other study identifiers
Name FT596-101
Source weblink https://clinicaltrials.gov/ct2/show/NCT04245722
Public contact
Email clinical@fatetherapeutics.com
Public email clinical@fatetherapeutics.com
First name Rebecca
Last name Reynolds
Phone +1 (0)858-875-1800
United States
Sponsors Fate Therapeutics


Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Recruiting
Estimated number of participants 285